Ideaya Biosciences, Inc. · NASDAQ:IDYA
Ideaya Biosciences — Investor Presentation (June 2020)
23 slides from Ideaya Biosciences's investor presentation, Jun 16, 2020
Slide 1: Improving Lives Through Transformative Precision Medicines
Improving Lives Through Transformative Precision Medicines June 2020 Exhibit 99.2 Ideaya Biosciences Nasdaq: IDYA
Slide 2: Forward-looking statements
Certain statements in this presentation and the accompanying oral commentary are forward-looking statements. These statements relate to future events or the future financial performance of IDEAYA Biosciences, Inc. (the “Company”) and involve known and unknown risks, uncertainties and other factors t
Slide 3: IDEAYA's Precision Medicine Oncology Pipeline
Indication Biomarker Preclinical IND Phase 1 Phase 2 Status Collaboration IDE397 MAT2A Solid Tumors MTAP Targeting IND Q4 2020 PARG Solid Tumors Novel Biomarker In vivo Efficacy Polq Solid Tumors HRD In vivo Efficacy WRN Solid Tumors High-MSI Cell Activity DDT Solid Tumors Novel Biomarker Target Val
Slide 4: Synthetic Lethality is an Emerging Field of Human Genetics Research and Precision Medicine Oncology
Synthetic Lethality is an Emerging Field of Human Genetics Research and Precision Medicine Oncology Synthetic lethality occurs when the simultaneous perturbation of two genes results in cell death Synthetic lethal genetic interactions with tumor-specific mutations may be exploited to develop antican
Slide 5: Fully-Integrated Target, Biomarker, and Drug Discovery Capabilities
Fully-Integrated Target, Biomarker, and Drug Discovery Capabilities SL Target & Biomarker Discovery & Validation Dual CRISPR, CRISPR, siRNA Bioinformatics Genetically Engineered Models Drug Discovery Structure Based Drug Design Small Molecule Chemistry Protein Degrader Capabilities Potential 1st-in-
Slide 6: IDEAYA Team and Scientific Advisory Board
IDEAYA Team and Scientific Advisory Board Scientific Thought Leaders in Synthetic Lethality and Precision Medicine Oncology IDEAYA Executives & R&D Leadership IDEAYA Scientific Advisory Board Yujiro Hata, M.B.A. President, Chief Executive Officer, Director Paul Stone, J.D. SVP, Chief Financial Offic
Slide 7: IDEAYA is Advancing the Next Generation of Synthetic Lethality Therapies
IDEAYA is Advancing the Next Generation of Synthetic Lethality Therapies PARP HRD/BRCA Lynparza (AZ) Zejula (GSK) Rubraca (Clovis) Talzenna (Pfizer) Today IDEAYA Synthetic Lethality Pipeline MAT2A MTAP-Deletion WRN High-MSI Target Discovery SL Targets Polq HRD PARG Replication Stress Novel Biomarker
Slide 8: IDEAYA and GSK Strategic Partnership
IDEAYA and GSK Strategic Partnership Landmark Partnership in Synthetic Lethality Validates IDEAYA Synthetic Lethality platform Enhances collective leadership in Synthetic Lethality Creates strategic combination opportunities Transformative Strategic Partnership Targets: MAT2A, Pol Theta and Werner H
Slide 9: IDEAYA and GSK Strategic Partnership: Strategic Combinations
IDEAYA and GSK Strategic Partnership Partnership Enables Strategic Combinations IDE397 MAT2A GSK3368715 (Ph 1) Type I PRMT + Pol Theta Small Molecule Inhibitor or Protein Degrader Zejula™ PARP + Patient Population MTAP Deletion BRCA/HRD MAT2A + Type I PRMT Clinical Combination [COMPANY LOGO]
Slide 10: MTAP Deletion Prevalence and MTAP-MAT2A Synthetic Lethality Biology
MTAP Deletion Prevalence MTAP-MAT2A Synthetic Lethality Biology MAT2A Inhibition is Synthetic Lethal with MTAP Deletion MTAP Deletion Prevalence ~15% of all Solid Tumors Data from The Cancer Genome Atlas in cBioPortal Cancer Type N MTAP Deletions (%) Glioblastoma 592 41 Mesothelioma 87 32 Esophageal
Slide 11: IDEAYA MAT2A Inhibitors Demonstrate Synthetic Lethality in MTAP-/- Cell Lines
IDEAYA MAT2A Inhibitors Demonstrate Synthetic Lethality in MTAP-/- Cell Lines & PD Modulation of SAM Levels Structurally Enabled Lead Optimization Lead series includes multiple compounds with nM potency and >5x IC50 ratio in HCT116 wt vs MTAP -/- Synthetic Lethality in HCT116 Cell Line Consistent se
Slide 12: IDE397: MAT2A Development Candidate Nominated
IDE397: MAT2A Development Candidate Nominated Targeting IND in Q4 2020 Significant reduction in tumor SAM levels with IDE397 at 5 mg/kg Tumor Pharmacodynamic Effect IDE397 (5 mg/kg) demonstrates greater tumor growth inhibition at 1/60th the dose vs AGI-25696 Published AG-270 preclinical dose is typi
Slide 13: IDE397 Differentiated Profile vs Agios Compounds
IDB397 demonstrates efficacy at 1/30th of the dose of Agios MAT2A compound (see data) IDE397: MAT2A Development Candidate Nominated Differentiated Profile vs Agios Compounds IDEAYA Data Keystone Symposium 2017 Agios Data Days post implant 15 20 25 30 35 0 250 500 750 1,000 1,250 1,500 +/- S.E.M. 79%
Slide 14: IDE397 Demonstrates Monotherapy Tumor Regression in MTAP-Deleted NSCLC Model
IDE397 produced dose-dependent efficacy in a NSCLC model with regression (TGI >100%) at 30 mg/kg IDE397 Demonstrates Monotherapy Tumor Regression in an MTAP-Deleted Endogenous NSCLC Model In Vivo Endogenous NSCLC MTAP (-/-) PDX Model IDEAYA Data [BAR CHART]
Slide 15: PARG plays a pivotal role in the regulation of DNA repair mechanisms
Poly(ADP-ribose) glycohydrolase (PARG) plays a pivotal role in the regulation of DNA repair mechanisms PARG hydrolyzes the linkages to break down PAR chains, completing the cycle of DNA repair August 2019 Dysfunction of Poly(ADP-ribose) Glycohydrolase Induces a Synthetic Lethality Effect in Dual Spe
Slide 16: PARG Drug Discovery Program
IDB-PARG Potency Biochemical IC50 7 nM PAR Foci cell EC50 50 nM Cell Viability EC50 510 nM Extensive research in PARG biology and chemistry Multiple collaborations ongoing to refine patient selection biomarker strategy IDEAYA has discovered potent PARG inhibitors SAR guided by structure-based drug d
Slide 17: PARG Monotherapy Tumor Regressions in Multiple PDX Models
IDEAYA-proprietary Novel Synthetic Lethality Biomarker Targeting PARG development candidate in 2021 PARG Synthetic Lethality Program Monotherapy Tumor Regressions Observed in Multiple PDX Models IDB-PARG Demonstrates In Vivo Tumor Regressions in Multiple PDX Models IDEAYA Data [BAR CHART]
Slide 18: Project Drive: Werner is essential in MSI-high cancer cell lines
Project Drive: Werner is essential in MSI-high cancer cell lines Werner Syndrome Helicase is Required for the Survival of Cancer Cells with Microsatellite Instability IDEAYA Publication Discovery: multiple hit discovery campaigns using a range of screening formats and compound libraries completed Sc
Slide 19: WRN Inhibitors Phenocopy Genetic Knockdown
WRN Inhibitors Phenocopy Genetic Knockdown WRN Inhibitor Cellular PD and Viability WRN inhibitor WRN siRNA Werner Helicase Synthetic Lethality Program Candidate Biomarker: High-MSI (15% GI Cancers and 16% CRC) IDEAYA Data PD-marker: dose dependent increase of DNA damage marker gH2AX demonstrated at
Slide 20: Polq Inhibitor In Vivo Activity
Polq Inhibitor In Vivo Activity Polq Inhibitor Cell Viability and Synergy PolQ Polq-1 as single agent and in combo with PARPi Polq-1 exhibits significant tumor growth inhibition in DLD1 BRCA2-/- xenograft model as a single agent Polq-1 and Olaparib combination demonstrates significant tumor growth i
Slide 21: MEK Clinical Combination with Pfizer Collaboration
MEK Clinical Combination FPI targeted June 2020 Pfizer Clinical Trial Collaboration and Supply Agreement IDE196 + MEKi (binimetinib) Synergy Metastatic Uveal Melanoma (MUM) IDE196 + MEK Combo IDE196 IDE196 Phase 1/2 Clinical Program Summary IDE196 + MEK inhibitor (binimetinib) combination clinical t
Slide 22: Biological Rationale for PKC + MEK Combination
AEB071 = 1st generation PKC inhibitor; MEK162 = binimetinib PKC + MEK Synergy MEL-202 Uveal Melanoma Cells Combo Rationale to Target PKC and MEK in the MAP-Kinase Pathway to Enhance Clinical Activity Combined PKC and MEK Synergistically Induced Tumor Regressions (92.1 Uveal Melanoma Xenograft) Biolo
Slide 23: Pipeline Target Milestones through 2021
Indication Biomarker Preclinical IND Phase 1 Phase 2 Target Milestone through 2021 Collaboration IDE397 MAT2A Solid Tumors MTAP IND Q4 20 Phase 1 Initiation H1 2021 PARG Solid Tumors Novel Biomarker In vivo Efficacy 2020 Development Candidate 2021 Polq Solid Tumors HRD Development Candidate 2020 IND
IDEAYA Biosciences — Investor Presentation (June 2020) on 6ix